Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002651842 | SCV003525603 | uncertain significance | not provided | 2024-04-10 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 162 of the CFI protein (p.Gly162Asp). This variant is present in population databases (rs546607673, gnomAD 0.006%). This missense change has been observed in individual(s) with clinical features of CFI-related conditions (PMID: 18557729, 20059470, 22710145, 25788521, 28942469, 31440263). ClinVar contains an entry for this variant (Variation ID: 2203563). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects CFI function (PMID: 32510551, 32908800, 37363824). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV002651842 | SCV005046484 | likely pathogenic | not provided | 2022-04-06 | criteria provided, single submitter | clinical testing | PS3, PS4_moderate |